Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial.

Despite such α-diversity increase, the d-FMT arm also showed a higher percentage of baseline species lost compared with the p-FMT arm, with a significant difference between arms only at week 4 follow-up (median 19.9% versus 14.8%, P = 0.045) but with a clear trend across other follow-up timepoints (Fig. 3e ).

also in 19,460 other papers

We also found a borderline significant association between the proportion of species immediately lost after treatment (week 1 follow-up) and the 12-month PFS in the d-FMT group but not in the p-FMT group.

also in 11,409 other papers